​

Artiva Biotherapeutics (ARTV) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ARTV Stock Forecast

Artiva Biotherapeutics (ARTV) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $37.50, with a high of $40.00 and a low of $35.00. This represents a 251.12% increase from the last price of $10.68.

ARTV Stock Rating

Artiva Biotherapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

ARTV Price Target Upside V Benchmarks

TypeNameUpside
StockArtiva Biotherapeutics251.12%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts222
Avg Price Target$37.50$37.50$37.50
Last Closing Price$10.68$10.68$10.68
Upside/Downside251.12%251.12%251.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 2615---6
Apr, 2615---6
Mar, 2615---6
Feb, 2615---6
Jan, 2615---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 11, 2026David NierengartenWedbush$40.00$11.15258.74%274.53%
May 08, 2026H.C. Wainwright$35.00$11.84195.61%227.72%
Aug 13, 2024David NierengartenWedbush$18.00$11.2260.43%68.54%
Aug 13, 2024Gil BlumNeedham$23.00$11.22104.99%115.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 12, 2026NeedhamBuyBuyhold
May 11, 2026WedbushOutperformOutperformhold
May 08, 2026H.C. WainwrightBuyBuyhold
Oct 17, 2025WedbushOutperformOutperformhold
Dec 30, 2024H.C. WainwrightBuyinitialise
Sep 03, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024NeedhamBuyinitialise
Aug 13, 2024WedbushOutperforminitialise
Aug 13, 2024Cowen & Co.Buyinitialise
Aug 13, 2024Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 24 Dec 25
Dec 24Dec 25
Reported$-5.20$-3.43
Avg Forecast$-4.95$-2.83
High Forecast$-3.63$-2.42
Low Forecast$-6.25$-3.21
Surprise %5.05%21.20%

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 24 Dec 25
Dec 24Dec 25
Reported$251.00K-
Avg Forecast$400.00K$75.36M
High Forecast$550.00K$75.36M
Low Forecast$250.00K$75.36M
Surprise %-37.25%-

Net Income Forecast

$-85M $-72M $-59M $-46M $-33M $-20M Dec 24 Dec 25
Dec 24Dec 25
Reported$-58.49M$-83.86M
Avg Forecast$-46.31M$-26.47M
High Forecast$-33.96M$-22.64M
Low Forecast$-58.47M$-30.03M
Surprise %26.32%216.79%

ARTV Forecast FAQ

Is Artiva Biotherapeutics stock a buy?

Artiva Biotherapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Artiva Biotherapeutics is a favorable investment for most analysts.

What is Artiva Biotherapeutics's price target?

Artiva Biotherapeutics's price target, set by 4 Wall Street analysts, averages $37.5 over the next 12 months. The price target range spans from $35 at the low end to $40 at the high end, suggesting a potential 251.12% change from the previous closing price of $10.68.

How does Artiva Biotherapeutics stock forecast compare to its benchmarks?

Artiva Biotherapeutics's stock forecast shows a 251.12% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Artiva Biotherapeutics over the past three months?

  • May 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.